On this page
  1. Two diabetes copies, then a weight
  2. Synthetic peptide, reference product a
  3. Canada did not say about price
  4. The United States is a different file
  5. Questions
  6. Sources

The brand-name file is the GLP-1 drugs list. Ozempic vs Wegovy is why those two Novo Nordisk products are not interchangeable. This page is the generic record in Canada.

Two diabetes copies, then a weight-management copy

Health Canada's June 29, 2026 news release called Sevmia the third generic semaglutide product the department had approved. The first two are the diabetes submissions.

Dr. Reddy's Laboratories Ltd filed an abbreviated new drug submission for Semaglutide Injection 2 mg/1.5 mL and 4 mg/3.0 mL, both 1.34 mg/mL. The regulatory decision summary says the Canadian reference product is Ozempic, and the use is once-weekly treatment of adults with type 2 diabetes to improve glycemic control. The notice of compliance is dated April 28, 2026, and it lists DINs 02567814 and 02567806. The Drug Product Database page opened for DIN 02567814 on October 26 listed status Marketed, original market date May 6, 2026, and a monograph date of April 28, 2026. The description on that page says the pen dispenses 1 mg doses.

Apotex's diabetes submission is Apo-Semaglutide Injection 2 mg/3 mL (0.68 mg/mL) and 4 mg/3.0 mL (1.34 mg/mL). The regulatory decision summary, decision date May 1, 2026, again names Ozempic as the reference product and the same adult diabetes use. It lists DINs 02568020 and 02568012. The Drug Product Database page for DIN 02568012 listed status Marketed, original market date May 14, 2026, and a monograph date of May 1, 2026. This page did not open a separate market-date line for DIN 02568020.

Sevmia is the weight-management submission. The notice of compliance dated June 29, 2026 names Apotex, the reference product Wegovy, and one strength: semaglutide 4 mg/3 mL, DIN 02569582. The regulatory decision summary, decision date June 25, 2026, says Sevmia is indicated as a once-weekly treatment for chronic weight management in adults and in children 12 years and older, with a reduced-calorie diet and increased physical activity. Health Canada's news release the same day uses that indication and calls Sevmia a generic version of Wegovy. The Drug Product Database page returned in the October 26 search listed status Approved, not Marketed, with status date June 29, 2026, and described the pen as dispensing 1 mg doses. A direct fetch of that URL later the same day returned a maintenance page, so the Approved status is from the search snapshot, not from a second live open.

Also on this siteWhat happens when you stop semaglutideWhat happens when you stop semaglutide? Two-thirds of the weight came back.The STEP 1 follow-up tracked 327 people for a year after they stopped. The year after stopping is the part nobody posts about.See the year-after numbers

A pen described as dispensing 1 mg doses is not, on that description, the 2.4 mg Wegovy maintenance strength and it is not the 7.2 mg pen. Health Canada's phrase "generic version of Wegovy" is the department's conclusion for the strength it authorized. It is not a finding that every Wegovy pen now has a generic twin.

Synthetic peptide, reference product a biologic

The decision summaries say Ozempic and Wegovy are biologic drugs made with recombinant DNA, and that the generic active ingredient is produced by solid-phase chemical synthesis, not by recombinant DNA. Health Canada still issued the notices. For each file, the summary says the sponsor showed pharmaceutical equivalence, cell-based assays showed comparable potency, and in vivo bioequivalence studies were not required because of that chemistry package plus what the summary calls semaglutide's uncomplicated pharmacokinetic characteristics. Each summary also records a notice of deficiency on impurities, stability, or the equivalence package, and says the sponsor's later data addressed it.

Read this next GLP-1 drugs list

That is a regulator's equivalence decision for a specific submission. It is not a sentence that says the pen in a pharmacy is identical to the reference pen in every strength.

What Canada did not say about price

The June 29 news release says many generic medications in Canada are 45 to 90 percent cheaper than the brand-name versions. That sentence covers many generic drugs. It does not state a semaglutide price or a Sevmia price. This page did not open a provincial formulary listing for these DINs. USD and CAD are different tags. No converted price appears here.

The same release said Health Canada was reviewing six other generic semaglutide submissions and expected more decisions in the weeks and months after June 29. This page did not find a later official tally of those six.

The United States is a different file

On April 10, 2026, Apotex Corp. announced that FDA had granted tentative approval for an abbreviated new drug application for semaglutide injection, developed with Orbicular. The release says that upon becoming eligible for final approval, the product would be expected to reach patients. Tentative approval, in that release, is not final approval. This page did not download the Orange Book on October 26, so it does not state a patent date or a launch date. No FDA approval that would put a generic semaglutide pen on a US pharmacy shelf was opened.

Also on this siteSemaglutide vs tirzepatideSemaglutide vs tirzepatide: one lost 20.2%, the other 13.7%.SURMOUNT-5 put both drugs in the same 72-week trial. Tirzepatide took the bigger number. The gap is real. What it leaves out matters too.See the head-to-head

A compounded semaglutide preparation is not this Canadian generic and it is not an FDA-approved generic. The US compounding calendar is compounded semaglutide vs Ozempic. The Wegovy tablet, which FDA approved in the US and which the October 17 Canadian check did not find, is the Wegovy pill.

Common questions

Is generic semaglutide approved in Canada?

Yes, as specific products. Health Canada authorized Dr. Reddy's and Apotex diabetes injections in April and May 2026, with Ozempic as the reference product, and authorized Sevmia on June 29, 2026, with Wegovy as the reference product.

Is generic Ozempic the same as generic Wegovy?

No. The April 28 and May 1 files name Ozempic and a diabetes use. The June 29 Sevmia file names Wegovy and chronic weight management. A marketed diabetes pen is not a finding that the product matches Wegovy.

Is Sevmia on pharmacy shelves?

The notice of compliance is June 29, 2026. The Drug Product Database snapshot opened October 26 listed the status as Approved, with status date June 29, 2026, and the description said the pen dispenses 1 mg doses. This page did not confirm a Marketed status for that DIN.

Is there a generic semaglutide in the United States?

Apotex announced an FDA tentative approval on April 10, 2026, and said final approval was still ahead. This page did not open an Orange Book file showing a marketed US generic.

What does a generic cost in Canada?

Not established here. Health Canada's 45 to 90 percent line was about many generic drugs, not a price for these DINs. No formulary price was collected.

Sources

Methodology. Status checked October 26, 2026 against Health Canada notices of compliance, regulatory decision summaries, Drug Product Database product pages that loaded, and Health Canada's June 29, 2026 news release. The Sevmia database page loaded in search results and later returned a maintenance notice on a direct fetch. The US statement is Apotex's April 10, 2026 release. The Orange Book was not downloaded. Prices were not collected.

Primary sources.